Stability analysis on the radioactive iodine-labelled prostate cancer-specific recombinant oncolytic adenovirus.

阅读:8
作者:Zhou Jiahe, Hao Lin, Shi Zhenduo, Ning Songyi, He Houguang, Zhao Yan, Dong Yang, Li Zhigang, He Jiuxiang, Zang Guanghui, Han Conghui
The aim of the present study was to construct the (125)I-replication-selective oncolytic adenovirus (RSOAds)-human telomerase reverse transcriptase (hTERT)/prostate specific antigen (PSA) nuclide-oncolytic virus marker by labelling the hTERT/PSA double-regulation replicative oncolytic adenovirus with (125)I nuclide, and investigate the influence of viral markers under various reaction conditions on labelling efficiency. N-bromosuccinimide (NBS) was used as the oxidizer for (125)I labelling, and the best conditions for labelling were identified through the reactions between oncolytic adenovirus at various concentrations and NBS. Dosage of (125)I, reaction duration, pH values and reaction volume were respectively evaluated to determine their effects on the labelling efficiency of (125)I-RSOAds-hTERT/PSA nuclide-oncolytic adenovirus markers. Purified nuclide-oncolytic adenovirus markers were isolated by gel-filtration chromatography; paper chromatography was performed to assay the radiochemical purity of (125)I-RSOAds-hTERT/PSA markers at various time points. Radiochemical purity of (125)I-RSOAds-hTERT/PSA was >95%, and could be maintained at 4°C for 7 days. The best reaction conditions were set as follows: 0.5 µl of (125)I (~0.2 m Ci, 7.4 MBq); 25 qg of NBS; 100 µl of 8×10(9) VP/ml (125)I-RSOAds-hTERT/PSA virus solution; 30 min of reaction duration; pH 7.5; 120 µl of PBS. Labelling hTERT/PSA double-regulation replicative oncolytic adenovirus with (125)I was identified to be available, and the radiochemical purity of acquired virus markers could be maintained under specific conditions.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。